Cancer Clinical Trials | Norton Healthcare Louisville, Ky.

Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Norton Cancer Institute clinical trials include:

Advanced Malignancies

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell […]

Advanced Malignancies

An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer

Advanced Malignancies

A PHASE 1B OPEN-LABEL DOSE ESCALATION TRIAL OF THE SAFETY OF, AND ANTIGEN-SPECIFIC IMMUNE RESPONSES ELICITED BY, VB10.NEO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC TUMORS

Advanced Solid Tumors

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Advanced Solid Tumors

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Advanced Solid Tumors

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Advanced Solid Tumors

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumors with KRasG12C Mutation

Advanced Solid Tumors

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Advanced Solid Tumors

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Advanced Solid Tumors

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies

Advanced Solid Tumors

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the treatment of adult patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL)

Advanced Solid Tumors

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

Advanced Solid Tumors

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors

Advanced Solid Tumors

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of Escalating Doses Of Pf-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal […]

Advanced Solid Tumors

A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors

Advanced Solid Tumors

An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had […]

Advanced Solid Tumors

A randomized, open-label, multicenter, phase 1b/2 trial evaluating the safety and efficacy of intratumorally-administered ilixadencel in combination with checkpoint inhibitor (CPI) in advanced cancer patients who are candidates for CPI therapy

Advanced Solid Tumors

A Phase 1/2 Dose Escalation And Dose Expansion Study Of Ba3011 Alone And In Combination With Nivolumab In Adult And Adolescent Patients 12 Years And Older With Advanced Solid Tumors

Advanced Solid Tumors

An Open-Label Study of ALPN-202 in Subjects with Advanced Malignancies (NEON-1)

Astrocytoma

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Biliary Tract Cancer

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

Bladder Cancer

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)

Bladder Cancer

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder […]

Bladder Cancer

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Bladder Cancer

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Bladder Cancer

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a

Cholangiocarcinoma

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Colorectal Cancer

Phase II study for the treatment of HER2- positive locally advanced unresectable or metastatic colorectal cancer subjects (CRC)

Colorectal Cancer

A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2)

COVID-19

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EB05 + SOC VS. PLACEBO + SOC IN ADULT HOSPITALIZED PATIENTS WITH COVID-19

Endometrial Cancer

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer […]

Esophageal Cancer

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center International Study of Durvalumab Given Concurrently with Definitive Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Gastric Cancer

A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)

Gastric Cancer

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Posit

Gastric Cancer

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and astroesophageal Cancer (GC/GEJC)

Glioblastoma

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Glioblastoma

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Head and Neck Cancer

An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) […]

Head and Neck Cancer

NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Head and Neck Cancer

Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer (HNSCC) and High-risk […]

Head and Neck Cancer

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

Hematological Malignancies

A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Combination with SOC Therapies in Subjects with Relapsed and Refractory Hematological Malignancies.

HR Positive

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Kidney Cancer

MK6482-013: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Kidney Cancer

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Leukemia

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dociparstat sodium in combination with standard chemotherapy for the treatment of newly-diagnosed acute myeloid leukemia

Leukemia

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Leukemia

A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes

Leukemia

Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination with Azacitidine in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)

Leukemia

A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination with Azacitidine and/or Venetoclax in Subjects with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Leukemia

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)

Leukemia

TWT-202 – Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a single agent or in Combination with Azacitidine or Decitabine in Patients with […]

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Leukemia

Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 […]

Leukemia

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)

Leukemia

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

Leukemia

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Leukemia

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Leukemia

A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 inParticipants with Acute Leukemia

Leukemia

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

Leukemia

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Leukemia

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated […]

Leukemia

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Leukemia

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

Lymphoma

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2

Lymphoma

A Phase I/II Trial Of Mosunetuzumab (BTCT4465A) As Consolidation Therapy In Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy And As Therapy In Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable […]

Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Lymphoma

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

Lymphoma

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies

Lymphoma

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Lymphoma

An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies

Lymphoma

Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center […]

Lymphoma

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Lymphoma

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Lymphoma

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Lymphoma

A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO–501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Lymphoma

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Lymphoma

A SINGLE-ARM, OPEN-LABEL, PHASE 1 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL OR […]

Lymphoma

Phase 1b/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Melanoma

Phase 2 study to characterize an injectable oncolytic virus therapy (viral immunotherapy) with and without concurrent anti PD-1 administration in unresectable PD-1 refractory advanced melanoma

Melanoma

Phase 2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy in Patients With Advanced Melanoma Who Have Previously Received anti-PD-[L]1 Therapy – ARTISTRY-6

Melanoma

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)

Merkel Cell Carcinoma

A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy

Merkel Cell Carcinoma

Phase 2 Study of INCMGA00012 in Patients with Metastatic Merkel Cell Carcinoma (POD1UM-201)

Miscellaneous Malignancies

A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Multiple Myeloma

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Open-label, Multicenter, Non-randomized Phase 2 Study OF PF-06863135 Monotherapy in PARTICIPANTS WITH Multiple Myeloma WHO ARE REFRACTORY TO At LEAST One PROTEASOME Inhibitor, ONE immunomodulatory drug and ONE anti-cd38antibody

Multiple Myeloma

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as […]

Multiple Myeloma

A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to Lenalidomide

Multiple Myeloma

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer […]

Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC

Non-Small Cell Lung Cancer (NSCLC)

Phase 2 multicenter, open-label, 2-cohort study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2, antibody drug conjugate (ADC) for HER 2-over-expressing or mutated unresectable and/or metastatic non-small cell lung cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III […]

Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer […]

Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT […]

Non-Small Cell Lung Cancer (NSCLC)

Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab

Non-Small Cell Lung Cancer (NSCLC)

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor […]

Oropharyngeal Cancer

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Ovarian Cancer

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Ovarian Cancer

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Pancreatic Cancer

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Prostate Cancer

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX:CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)

Prostate Cancer

A Phase 1b Study Evaluating the Safety and Efficacy of Multiple Therapies in Subjects With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

An Expanded/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) and Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either […]

Registry

Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system (LAANTERN) Prospective Registry

Sarcoma

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR […]

Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Squamous Cell Carcinoma

A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS […]

Squamous Cell Carcinoma

A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for […]

Squamous Cell Carcinoma

A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma

Phase III Study of Buparlisib (AN2025) Plus Paclitaxel Compared to Paclitaxel Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Triple Negative Breast Cancer (TNBC)

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Triple Negative Breast Cancer (TNBC)

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

Six years after his glioblastoma diagnosis, a brain cancer survivor and his wife look back

John and Jessica Bostock were in the middle of exciting life changes as the summer of 2015 started warming up. John was just 35, and the couple had an 18-month-old daughter, Olive. Plans were underway […]

Read Full Story

Three-time cancer survivor encourages others

Bruce Lowe does not take being a cancer survivor for granted. Indeed, surviving three different cancers has given him a mission. “My doctor told me that I had stage 4 incurable bone cancer and had […]

Read Full Story

The latest in noninvasive brain tumor treatment

TrueBeam, CyberKnife and Gamma Knife may sound like superheroes, but actually they are tools for treating brain tumors. These three machines are used for stereotactic radiosurgery (SRS), a non-surgical treatment option that uses high doses […]

Read Full Story

Celebrating cancer survivors and giving them a care plan for a long life

June 6 is National Cancer Survivors Day — a time to celebrate the strength and courage of survivors, their families and caregivers. It’s a good time to remember that life after cancer can be fulfilling, […]

Read Full Story

How to talk to your doctor about sex and cancer

Sexual health is important for any adult’s well-being, but patients with cancer face a new set of challenges when it comes to sexuality. Laila S. Agrawal, M.D., breast cancer oncologist with Norton Cancer Institute, is […]

Read Full Story
Related Stories

Six years after his glioblastoma diagnosis, a brain cancer survivor and his wife look back

John and Jessica Bostock were in the middle of exciting life changes as the summer of 2015 started warming up. John was just 35, and the couple had an 18-month-old daughter, Olive. Plans were underway […]

Read Full Story

Three-time cancer survivor encourages others

Bruce Lowe does not take being a cancer survivor for granted. Indeed, surviving three different cancers has given him a mission. “My doctor told me that I had stage 4 incurable bone cancer and had […]

Read Full Story

The latest in noninvasive brain tumor treatment

TrueBeam, CyberKnife and Gamma Knife may sound like superheroes, but actually they are tools for treating brain tumors. These three machines are used for stereotactic radiosurgery (SRS), a non-surgical treatment option that uses high doses […]

Read Full Story

Celebrating cancer survivors and giving them a care plan for a long life

June 6 is National Cancer Survivors Day — a time to celebrate the strength and courage of survivors, their families and caregivers. It’s a good time to remember that life after cancer can be fulfilling, […]

Read Full Story

How to talk to your doctor about sex and cancer

Sexual health is important for any adult’s well-being, but patients with cancer face a new set of challenges when it comes to sexuality. Laila S. Agrawal, M.D., breast cancer oncologist with Norton Cancer Institute, is […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.